Info@ThinkPinkRocks.com

Forest Laboratories’ Colobreathe dry powder inhaler receives EMA approval

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, today announced that it has been granted European Medicines Agency (EMA) approval to market Colobreathe dry powder colistimethate sodium for inhalation for treating cystic fibrosis patients aged 6 years and older with chronic lung infection caused by P. aeruginosa.

View post:
Forest Laboratories’ Colobreathe dry powder inhaler receives EMA approval

Share
1 Comment
  1. You really make it seem really easy along with your presentation but I find
    this topic to be really something that I believe I might never understand.

    It seems too complicated and very broad for me. I am looking forward in your subsequent publish, I will try
    to get the hang of it!

Leave a Reply